Cyclobenzaprine (Flexeril) Half-Life, Elimination, and Detection Window

Cyclobenzaprine (Flexeril) is a centrally acting skeletal muscle relaxant structurally related to tricyclic antidepressants.

Pharmacokinetics

ParameterValue
Elimination half-life (t½)8–37 hours (mean ~18 h). Highly variable (CYP450 metabolism, age, hepatic function).
Time to steady state~4 days (5 half-lives).
Full elimination~2–8 days (5 half-lives).
Onset of action1–2 hours.
Duration of effect4–6 hours (muscle relaxant); sedation longer.
Protein binding~93%.
MetabolismHepatic: CYP1A2, CYP3A4, CYP2D6 → norcyclobenzaprine (active), hydroxylated metabolites.
ExcretionRenal (metabolites), fecal.

Detection Windows

  • Urine: Up to 4–10 days (metabolites). Standard immunoassays may cross-react with TCAs.
  • Blood: 24–48 hours (parent drug).
  • Hair: Up to 90 days (chronic use).
  • Saliva: 24–36 hours.

Clinical Implications

  • Dosing: 5–10 mg TID (IR); 15–30 mg daily (ER). Elderly/hepatic impairment: start 5 mg, max 15 mg/day.
  • Accumulation: Significant with TID dosing — sedation, anticholinergic effects (dry mouth, constipation, urinary retention) worsen over days.
  • Drug interactions: MAOIs (contraindicated), CYP1A2 inhibitors (fluvoxamine, ciprofloxacin → ↑ levels), CNS depressants (additive sedation), serotonergic drugs (serotonin syndrome risk).
  • Withdrawal: Possible after prolonged use (nausea, headache, malaise) — taper.

The often-cited "1.5-hour half-life" is incorrect; that value may refer to the alpha distribution phase or a misinterpretation. The terminal elimination half-life is 8–37 hours.

Chronic Fatigue Syndrome - Related Articles